» Articles » PMID: 37811096

Olanzapine-induced Oculogyric Crisis in a Patient with Mania Without Psychotic Symptoms: a Case Report

Overview
Publisher Wolters Kluwer
Specialty Medical Education
Date 2023 Oct 9
PMID 37811096
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction And Importance: Oculogyric crisis (OGC), marked by upward eye deviation, is rare and linked to diverse causes, including drugs and neurological conditions. This study details a 16-year-old male's OGC onset after olanzapine treatment for an initial mania episode, highlighting the need to recognize this potential side effect.

Case Presentation: A 16-year-old male with nonpsychotic mania was treated with olanzapine and sodium valproate. On day 30, he developed OCG due to olanzapine, managed with medication. After discharge, similar ocular symptoms emerged. Gradual olanzapine tapering alongside anticholinergic administration led to symptom relief. The Young Mania Rating Scale score decreased; psychoeducation was provided to the patient and family.

Discussion: This study presents an exceptional case of olanzapine-induced OGC, a rare dystonic eye movement reaction. The patient's presentation matched OGC criteria, confirmed by a high Adverse Drug Reaction Probability Scale score. Unusually, symptoms appeared 30 days postolanzapine initiation. A thorough assessment ruled out alternative causes. Mechanisms, possibly related to dopamine-choline balance and receptor sensitivity, remain uncertain. Despite atypical antipsychotics' lower risk, olanzapine's moderate D2 receptor binding led to this unusual response. Management involved dose reduction and anticholinergic therapy.

Conclusion: This case report highlights the rare occurrence of olanzapine-induced OCG in a patient with nonpsychotic mania. Effective management requires proper history taking, examination, regular follow-up, monitoring, and appropriate medication use. The case demonstrates the need for caution when increasing olanzapine dose in manic patients with untreated mental illness and a history of neurological symptoms.

Citing Articles

Seeing beyond the norm: Unveiling ocular complications with atypical antipsychotics.

Bhardwaj A, Bhardwaj A, Bhumika , Sirowa A Ind Psychiatry J. 2025; 33(2):409-413.

PMID: 39898083 PMC: 11784664. DOI: 10.4103/ipj.ipj_134_24.


Systemic Medications and Their Ocular Side Effects.

Al-Namaeh M Cureus. 2025; 16(12):e74976.

PMID: 39744265 PMC: 11692015. DOI: 10.7759/cureus.74976.

References
1.
Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

2.
Bavle A, Kumar G . Olanzapine-induced Tardive Oculogyric Crises. Indian J Psychol Med. 2014; 35(4):423-4. PMC: 3868103. DOI: 10.4103/0253-7176.122249. View

3.
Faulk R, Gilmore J, Jensen E, Perkins D . Risperidone-induced dystonic reaction. Am J Psychiatry. 1996; 153(4):577. DOI: 10.1176/ajp.153.4.577a. View

4.
Barow E, Schneider S, Bhatia K, Ganos C . Oculogyric crises: Etiology, pathophysiology and therapeutic approaches. Parkinsonism Relat Disord. 2016; 36:3-9. DOI: 10.1016/j.parkreldis.2016.11.012. View

5.
Slow E, Lang A . Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment. Mov Disord. 2017; 32(2):193-202. DOI: 10.1002/mds.26910. View